This case outlines recurrent neutropenia after fourteen years of successful clozapine use. The patient has a diagnosis of treatment-resistant schizophrenia which has been complicated by sensitivity to side effects of haloperidol and past failure of antipsychotics to manage her symptoms. It was necessary for our patient to follow a complicated treatment path involving close monitoring of blood levels, admissions, the initiation of lithium and the regular use of filgrastim (Neupogen), granulocyte colony stimulating factor (G-CSF). Following a failure of rescue filgrastim to increase her neutrophil levels, a management protocol was designed with input from the on-site hematology team. This protocol involved the use of filgrastim on a regular p...
BACKGROUND: The use of clozapine is limited due to the occurrence of neutropenia, and the rare but l...
Background: Cladribine tablets were recently approved for the treatment of Relapsing-Remitting Multi...
While clozapine is an effective treatment for refractory schizophrenia, its use is limited by haemat...
Objective: Clozapine remains the most effective intervention for treatment resistant schizophrenia; ...
Objectives: This paper aims to report on a case in which re-challenging with clozapine in combinatio...
Clozapine is the antipsychotic of choice in the management of treatment resistant schizophrenia. Neu...
Background and Objectives: Clozapine is the only antipsychotic approved for treatment-resistant schi...
Objective: To report and review the use of cytokines for the treatment of clozapine-induced neutrope...
PURPOSE/BACKGROUND: Clozapine is associated with hematological abnormalities, with neutropenia and a...
Clozapine is the only drug with confirmed efficacy for refractory schizophrenia; however, its use is...
A case is presented of a 30-year-old female with treatment-resistant schizoaffective disorder who wa...
Background and Objectives: Clozapine is the only antipsychotic approved for treatment-resistant schi...
Background: Data on the haematological outcomes of patients who continue clozapine treatment followi...
Clozapine is a second-generation antipsychotic agent from the benzodiazepine group indicated for tre...
PURPOSE/BACKGROUND: Clozapine is associated with hematological abnormalities, notably neutropenia, w...
BACKGROUND: The use of clozapine is limited due to the occurrence of neutropenia, and the rare but l...
Background: Cladribine tablets were recently approved for the treatment of Relapsing-Remitting Multi...
While clozapine is an effective treatment for refractory schizophrenia, its use is limited by haemat...
Objective: Clozapine remains the most effective intervention for treatment resistant schizophrenia; ...
Objectives: This paper aims to report on a case in which re-challenging with clozapine in combinatio...
Clozapine is the antipsychotic of choice in the management of treatment resistant schizophrenia. Neu...
Background and Objectives: Clozapine is the only antipsychotic approved for treatment-resistant schi...
Objective: To report and review the use of cytokines for the treatment of clozapine-induced neutrope...
PURPOSE/BACKGROUND: Clozapine is associated with hematological abnormalities, with neutropenia and a...
Clozapine is the only drug with confirmed efficacy for refractory schizophrenia; however, its use is...
A case is presented of a 30-year-old female with treatment-resistant schizoaffective disorder who wa...
Background and Objectives: Clozapine is the only antipsychotic approved for treatment-resistant schi...
Background: Data on the haematological outcomes of patients who continue clozapine treatment followi...
Clozapine is a second-generation antipsychotic agent from the benzodiazepine group indicated for tre...
PURPOSE/BACKGROUND: Clozapine is associated with hematological abnormalities, notably neutropenia, w...
BACKGROUND: The use of clozapine is limited due to the occurrence of neutropenia, and the rare but l...
Background: Cladribine tablets were recently approved for the treatment of Relapsing-Remitting Multi...
While clozapine is an effective treatment for refractory schizophrenia, its use is limited by haemat...